How to choose a statin after kidney transplantation: case analyses

Transplantation Proceedings
K MuchaL Paczek

Abstract

Statins are effective to reduce total cholesterol and low-density lipoprotein fractions in a dose-dependent manner. Moreover, they have an excellent safety profile. Besides cholesterol-lowering properties, statins have additional actions described in the present case report. The diverse effects of these drugs means that many patients with different disease entities, such as cardiovascular diseases, can benefit from their effects. However, the problem of so called "class effect" remains controversial. The question whether each drug within the group is equivalent appears important, as long as statins must be taken long-term and as the therapy affects patient quality of life and survival. To address this question, we present two renal transplant recipients treated with statins. The induction of pharmacokinetic tolerance and damage to hepatic cells during administration of statins is discussed. Presented data suggest that the choice of statin should be based on individual patient requirements and adapted to the individual treatment response.

References

Apr 4, 1986·Science·M S Brown, J L Goldstein
Sep 7, 1995·The New England Journal of Medicine·J A KobashigawaG A Cogert
Apr 29, 1998·The American Journal of Medicine·J Shepherd
Jan 20, 1999·Circulation·C D Furberg
Feb 6, 1999·Journal of the American College of Cardiology·W H KaesemeyerR W Caldwell
Feb 12, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·H C BucherG H Guyatt
Mar 20, 1999·Transplantation Proceedings·A GórskiL Păczek
Jan 29, 2000·Journal of Clinical Pharmacy and Therapeutics·A Jardine, H Holdaas
Dec 29, 1999·Nature Medicine·M J Rogers
Nov 14, 2000·The American Journal of Cardiology·W C Cromwell, P E Ziajka
Dec 15, 2000·European Journal of Clinical Investigation·G TonoloM Maioli
Jun 20, 2003·Lancet·Hallvard HoldaasUNKNOWN Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators
Nov 22, 2005·Lancet Neurology·Leila A ShobabHoward H Feldman
Apr 22, 2006·International Journal of Clinical Pharmacology and Therapeutics·H HoldaasJ Denouel
Jul 23, 2008·Perspectives in Vascular Surgery and Endovascular Therapy·Kimon Bekelis, Nicos Labropoulos

❮ Previous
Next ❯

Citations

Jul 14, 2017·Clinical Diabetes and Endocrinology·Marcio W Lauria, Antonio Ribeiro-Oliveira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.